| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | 10 mg/ml concentrate for solution for infusion |
| Reference number | 3286 |
| Indication | Monotherapy treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal, squamous cell carcinoma (OSCC) after prior fluoropyrimidine- and platinum-based chemotherapy |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Immunological products & vaccines |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/12/2020 |
| NICE guidance | TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer |